An aggressive medical approach for inflammatory bowel disease: Clinical challenges and therapeutic profiles in a retrospective hospital-based series

Current Clinical Pharmacology

Volumn 7, Issue 3, 2012, Pages 209-213

  Actis, Giovanni C ^a   Rosina, Floriano ^b   Pellicano, Rinaldo ^a   Rizzetto, Mario ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b GRADENIGO HOSPITAL   (Italy)

Author keywords

Azathioprine; Crohn's disease; Cyclosporin; Inflammatory bowel disease; Mesalamine; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MESALAZINE;

ADOLESCENT; ADULT; AGED; ARTICLE; COLON RESECTION; DRUG FATALITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOPLASM; PANCREAS DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; COHORT STUDIES; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84862595559     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488412800958730     Document Type: Article

References (37)

1. Swaminath A, Kornbluth A. Optimizing drug therapy in inflammatory bowel disease. Curr Gastroenterol Rep 2007; 9: 513-20.
2. Alves A, Panis Y, Bouhnik Y, Maylin V, Lavergne-Slove A, Valleur P. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 2003; 197: 379-85.
3. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 4: 276-9.
4. Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroidrefractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007; 7: 13.
5. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009; 104: 2760-7.
6. Actis GC, Ciancio A, Lagget M, et al. Intravenous and oral cyclosporin in refractory ulcerative colitis: toxicity in a low-dose trial. Gastroenterology 1997; 112: A919.
7. Magnasco A, Rossi A, Catarsi P, et al. Cyclosporin and organ specific toxicity: Clinical aspects, pharmacogenetics and perspectives. Curr Clin Pharmcol 2008; 3: 166-73.
8. Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 937-43.
9. Actis GC, Debernardi-Venon W, Lagget M, et al. Hepatotoxicity of intravenous cyclosporin A in patients with acute ulcerative colitis on total parenteral nutrition. Liver 1995; 15: 320-3.
10. Actis GC, Ottobrelli A, Pera A, et al. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids. J Clin Gastroenterol 1993; 17: 10-3.
11. Van Assche G, D'Haens G, Noman M, et al. Randomized, doubleblind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
12. Teml A, Schaeffeler E, Herrlinger KR, Klotz U, Schwab M. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet 2007; 46: 187-208.
13. Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease in patients taking immunomodulators. Aliment Pharmacol Ther 2005; 22: 1-16.
14. Ansari A, Elliott T, Baburajan B, et al. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 734-41.
15. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008; 64: 753-67.
16. Kollek R, van Aken J, Feuerstein G, Schmedders M. Pharamacogenetics, adverse drug reactions, and public health. Community Genet 2006; 9: 50-4.
17. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.
18. van Schaik F, van Oijen MGH, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012; 61: 235-40.
19. Cheng Y, Desreumaux P. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J Gastroenterol 2005; 11: 309-14.
20. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002; 51: 536-9.
21. Gisbert JP, Luna M, González-Lama Y, et al. Effect of 5- aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol Hepatol 2008; 31: 477-84.
22. Brimblecombe R. Mesalazine: a global safety evaluation. Scand J Gastroenterol Suppl 1990; 172: 66.
23. Sossai P, Cappellato MG, Stefani S. Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine. Mt Sinai J Med 2001; 68: 389-95.
24. Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalaminerelated lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis 2003; 9: 308-15.
25. Actis GC, Ottobrelli A, Baldi S, et al. Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background: a case report. Mt Sinai J Med 2005; 72: 136-40.
26. Actis GC, Marzano A, Pellicano R, Rizzetto M. How important is mesalamine in the maintenance of steroid-refractory colitis? Inflamm Bowel Dis 2008; 14: 1026.
27. Stocco G, Martelossi S, Malusa' N, et al. Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse. Dig Dis Sci 2008; 53: 3246-9.
28. Cheifetz AS, Stern J, Garud S, et al. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol 2011; 45: 107-12.
29. Laharie D, Bourreille A, Branche J, et al. Cyclosporin versus infliximab in acute severe ulcerative colitis refractory to intravenous steroids: a randomized study. J Crohns Colitis 2011; 5: S8.
30. Sjöberg M, Walch A, Meshkat M, et al. Infliximab or cyclosporin as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis; a retrospective observational study. Inflamm Bowel Dis 2012; 18: 212-8.
31. Bryan S, Andronis L, Hyde C, Connock M, Fry-Smith A, Wang D. Infliximab for the treatment of acute exacerbations of ulcerative colitis. Health Technol Assess 2010; 14(Suppl. 1): 9-15.
32. Sprakes MB, Ford AC, Suares NC, et al. Costs of care for Crohn's disease following the introduction of infliximab: a single-center UK experience. Aliment Pharmacol Ther 2010; 32: 1357-63.
33. Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep 2008; 10: 585-90.
34. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99: 112-28.
35. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011; 60: 1739-53.
36. Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am J Gastroenterol 2011; 106: 1272-80.
37. Pagnini C, Saeed R, Bamias G, et al. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA 2010; 107: 454-9.